Lung transplant immunosuppression regimens generally include the calcineurin inhibitor tacrolimus. We hypothesized that mean residual expression (MRE) of calcineurindependent genes assesses rejection and infection risk better than does tacrolimus trough. We prospectively followed 44 lung allograft recipients at 2 to 18 months posttransplant and measured changes in whole blood interleukin-2, interferon-γ, and granulocyte-macrophage colony-stimulating factor gene expression following a tacrolimus dose. Posttransplant duration, immunosuppressive medication levels, and bronchoscopic rejection and infection assessments were compared with MRE by using generalized-estimating equation-adjusted models. Prednisolone effect on MRE was assessed ex vivo in blood samples from nontransplanted controls. Tacrolimus concentration inhibiting 50% of cytokine production (IC 50 ) was measured in a pretransplant subset.
Lung transplant immunosuppression regimens generally include the calcineurin inhibitor tacrolimus. We hypothesized that mean residual expression (MRE) of calcineurindependent genes assesses rejection and infection risk better than does tacrolimus trough. We prospectively followed 44 lung allograft recipients at 2 to 18 months posttransplant and measured changes in whole blood interleukin-2, interferon-γ, and granulocyte-macrophage colony-stimulating factor gene expression following a tacrolimus dose. Posttransplant duration, immunosuppressive medication levels, and bronchoscopic rejection and infection assessments were compared with MRE by using generalized-estimating equation-adjusted models. Prednisolone effect on MRE was assessed ex vivo in blood samples from nontransplanted controls. Tacrolimus concentration inhibiting 50% of cytokine production (IC 50 ) was measured in a pretransplant subset.
Results showed that MRE did not change with diagnosis of rejection but that airway infection was associated with a 20% absolute decrease (95% confidence interval 11%-29%). MRE increased with time after transplant but was not associated with tacrolimus trough. Interestingly, MRE correlated inversely with corticosteroid dose in the study cohort and ex vivo. Pretransplant tacrolimus IC 50 depended on the cytokine measured and varied between individuals, suggesting a range in baseline responses to tacrolimus. We conclude that MRE identifies infection risk in lung allograft recipients, potentially integrating calcineurin inhibitor and steroid effects on lymphocyte effector function.
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| INTRODUC TI ON
Tacrolimus is a critical component of most post-lung transplant maintenance immunosuppression regimens. 1 It is hoped that tacrolimus titration based on this assay could lead to decreased incidence of rejection, infection, and cancer in renal allograft recipients. 5, 6 Optimizing immunosuppression in lung allograft recipients remains challenging. In the first year after transplant, 35% of lung allograft recipients have at least 1 episode of acute rejection requiring treatment. 7 Acute cellular rejection is a risk factor for chronic lung allograft dysfunction (CLAD), which affects nearly 50% of patients at 5 years and is the most significant cause of death after the first year. 7, 8 Acute cellular rejection and CLAD occur despite high doses of tacrolimus combined with mycophenolate mofetil and prednisone. At the same time, these immunosuppression regimens have been linked with increased rates of infection and malignancy. 9 The difficulties tailoring immunosuppressive therapy for lung transplant recipients have fueled demand for a blood-based assay to monitor the immune system. The ImmuKnow assay measures CD4 + T cell production of ATP in response to stimulation with phorbol 12-myristate 13-acetate (PMA). However, enthusiasm for this assay diminished after studies demonstrated poor test characteristics for diagnosing infection and rejection in lung transplant recipients. 10 The MRE assay is thought to be more specific to tacrolimus because the comparison of peak and trough gene expression can mitigate impacts of peripheral blood mononuclear cell (PBMC) lymphocyte count and of other immunosuppressive medications. 11, 12 The use of ionomycin to trigger calcium-dependent NFAT signaling and the measurement of the expression of genes under the NFAT promoter should further enhance the specificity for calcineurin inhibitors.
This MRE assay has shown early success in monitoring kidney, liver, and heart allograft recipients. 3, 13, 14 However, the specificity of this assay for tacrolimus dosing and performance characteristics in identifying infection and rejection risk previously have not been evaluated in lung allograft recipients. We hypothesized that MRE levels would be associated with the level of tacrolimus-based immunosuppression and could identify lung transplant recipients at increased risk for infection or rejection. were recruited 1 to 2 months after transplant and followed for 6 to 18 months after transplant. Subjects not treated with tacrolimus were excluded. All subjects provided written informed consent.
| MATERIAL S AND ME THODS

| Study population
Immunosuppression practices followed institutional protocols. Induction regimens included basiliximab and methylprednisolone. In the absence of rejection, prednisone was administered at 20 mg daily for the first 3 months, tapered to 0.2 mg/kg daily over the next 3 months, and then gradually tapered to 0.1 mg/kg by 12 months. Targeted tacrolimus troughs were 10 to 14 ng/mL in the first 3 months, 10 to 12 ng/mL in the next 3 months, and 8 to 10 ng/ mL thereafter. Mycophenolate mofetil was started in the immediate postoperative period targeting 2 g daily in divided doses but could be reduced or stopped in the setting of leukopenia, skin cancer, or other side effects.
| Predictor variables: MRE and flow cytometric assays
MRE assays were performed within 1 day of a bronchoscopy. Briefly, 
| Outcome measures
Acute cellular rejection and bronchoscopically detected infection 
| Sample size and statistical analysis
The target enrollment was 50 subjects, which was estimated to provide 97% power to identify subjects at risk for acute cellular rejection and 89% power to identify subjects at risk for infections, assuming a 5% incidence of ≥A2 grade rejection and an 18% incidence of infection.
These power calculations were performed based on 2-sample t tests 17 with effective sample sizes adjusted for intracluster correlation. using the "pwr," "gee," "mgcv," and "nplr" packages. 17, 19, 20 
| RE SULTS
Subject characteristics of the included subject population are shown in Table 1 . Of the enrolled subjects, interstitial lung diseases and double lung transplants are more frequent than in ISHLT registry populations. 7 A flow diagram of subject enrollment and study sample collection is shown in the Supplement. There were 117 MRE assessments included on 44 subjects. Of these assessments, 17 were at the time of bronchoscopically detected infection and 11 were at the time of acute cellular rejection, including 2 events with concurrent infection and rejection.
To assess MRE assay reproducibility in our laboratory, we compared MRE values determined from a single study visit using 2 different quantitative PCR devices. After correcting for the small bias between the 2 devices described in Figure S2 , we found a correlation coefficient of 0.98 (95% confidence interval [CI] 0.94-0.99) for 17 paired MRE measurements, suggesting high reproducibility. There were no statistically significant associations between MRE and the time intervals between the tacrolimus doses or between tacrolimus dose and peak level blood draw ( Figure S3 ).
| Immunosuppression effects on MRE
MRE is expected to vary inversely with immunosuppression; thus, we predicted that MRE will increase over time posttransplant because of protocoled reductions in tacrolimus trough targets. As shown in Figure 1A , we did observe a positive correlation with time posttransplant, with MRE increasing an average of 0.35%
(95% CI 0.001-0.69) per week. While one might expect MRE levels to decrease with increasing trough tacrolimus levels, previous studies showed an association with tacrolimus peak but not with trough levels. 6 Similarly, we did not observe a significant association between MRE and tacrolimus trough (P = .11, Figure 1B) or daily dose (P = .47, not shown). There was also no association between MRE and daily mycophenolate mofetil dose (P = .46, Figure 1C ). However, MRE decreased 1.7% (95% CI 3.3-0.1) per additional 1 mg of daily prednisone ( Figure 1D ).
We sought to determine if prednisone could synergize with tacrolimus in repressing NFAT-dependent cytokine signaling, as suggested by Figure 1B . To model this ex vivo, we incubated whole blood from 5 nontransplanted control subjects with varying concentrations of prednisolone and 0 or 10 ng/mL tacrolimus and calculated the MRE.
Oral prednisone is converted into biologically active prednisolone, and transplant recipient plasma prednisolone concentrations are approximately 10 ng/mL per 1 mg of oral prednisone. 21 As shown in Figure 2 , we found that MRE peaked at the very low prednisolone concentration of 20 ng/mL, which is roughly equivalent to that produced by a 2-mg dose of prednisone. MRE was decreased at prednisolone levels equivalent to those seen in our study cohort of 100 and 200 ng/mL, corresponding to prednisone doses of 10 and 20 mg, respectively, compared with 0 or 20 ng/mL prednisolone (P ≤ .005). The effects of prednisone on each gene were similar in both the cohort and ex vivo studies.
| Association between MRE and primary outcomes
Our primary aim was to assess for an association between MRE and acute cellular rejection and bronchoscopically detected infection, analogous to what has been seen in the context of other solid organ transplants. As shown in Figure 3A , we did not observe differences in the distribution of (95% CI 11%-29%, P < .001, Figure 3B ). This difference remained when time posttransplant, tacrolimus trough, and prednisone dose were included in the GEE-adjusted model (β = 19%, 95% CI 9%-29%, P < .001).
Interestingly, subjects with concurrent rejection and infection at the time of MRE analysis had some of the lowest MRE values. We compared tacrolimus trough and MRE for an association with bronchoscopically detected infection risk by multivariable modeling (Figure 3C-D) , finding MRE to be superior to tacrolimus trough in assessing infection risk.
The hazard ratio (HR) for infection per 10% increase in MRE was 0.75 (95% CI 0.63-0.90, P = .001), while there was no statistically significant association between tacrolimus trough and infection risk (HR 1.06, 95%
CI 0.85-1.31, P = .62). There were no statistically significant interactions between week after transplant, infection, and prednisolone dose when these terms considered in pairwise manner in association with MRE.
However, a trend toward a negative interaction between week posttransplant and infection (P = .06) suggests that MRE might be lower in late infections. The hazard for infection appeared linear over a range of MRE values ( Figure 3D ). Of the 3 cytokines that make up the MRE value, IL-2 had the strongest association with infection risk.
| Pretransplant tacrolimus IC 50
We sought to determine the extent to which intrinsic subject characteristics contributed to the variability in immunosuppression as measured by MRE. In a post hoc analysis, we determined tacrolimus IC 50 values using flow cytometry for 21 of the subjects in our study for whom pretransplant PBMC samples were available. In addition to the IL-2 and IFN-γ cytokine production measured in the MRE assay, we Figure 4A , we observed 2-to 4-fold differences across individuals in the IC 50 for these cytokines pretransplant. Interestingly, there were also significant differences between cytokines, with IL-2 having the lowest IC 50 and TNF-α having the greatest. There were also statistically significant, positive correlations across individuals for most of the tested cytokine IC 50 values, suggesting that some individuals were generally more sensitive to tacrolimus than others. Contrary to our hypothesis, we did not observe an increase in mean MRE across subjects with increasing pretransplant tacrolimus IC 50
( Figure 3B ). We also did not find positive correlations between IC 50 and MRE of individual cytokines IL-2 and IFN-γ (not shown).
| D ISCUSS I ON
We found that suppressed MRE values were associated with bronchoscopically detected infections, independent of tacrolimus trough levels. MRE levels increased over time as immunosuppression was Previous studies in renal transplant identified an MRE cutoff of around 30% to discriminate between high and low risk of infection. 6 Similarly, we observed here that bronchoscopically detected infection was rare above an MRE value of 40%. Because of the repeat measure study design, we could not test for an association between MRE and infections not detected at the time of bronchoscopy, including extrapulmonary infections. These are potentially relevant as cytomegalovirus, for example, has been shown to lower MRE. 22 We did not observe differences in the risk of rejection based on MRE value. While missed study visits and a higher than expected standard deviation for observed MRE values diminished our statistical power somewhat, the available data suggest that MRE values may not be helpful in identifying lung allograft recipients at increased risk for rejection. Interestingly, the ImmunoKnow assay, which has the practical advantage of requiring only 1 blood sample, also performed better at assessing infection compared with rejection risk. 23 Compared with renal allografts, lung allografts may be more antigenic and require greater immunosuppression. 24 It is possible that variation in tacrolimus levels within the targets used early after lung transplant has little impact on the risk of rejection. Consistent with this notion, we previously reported a plateau in the risk of acute rejection as a function of tacrolimus trough beyond a level of 8 to 10 ng/mL. 25 NFAT signaling pathways may render the MRE assay dependent on other immunosuppressive medications. 27 Synergistic effects of steroids and calcineurin inhibitors may limit the specificity of the MRE assay as a measure of tacrolimus-mediated immunosuppression. 27, 28 An important finding is that immunosuppressive medication sensitivity, whether measured by MRE or by IC 50 , varies substantially between individuals. Because tacrolimus partitions into red blood cells, serum concentrations can be >10-fold lower than whole blood levels, so the observed IC 50 values occur within the range of plasma concentrations that are typical in transplant recipients. 29 It is intriguing to consider the potential impacts of variable activation of cytokines as tacrolimus concentrations fluctuate throughout the day. While we hypothesized that high IC 50 values would predict high average MRE, this was not observed. Although we measured IC 50 with IFN-γ, IL-2, and TNF-α production but MRE with IFN-γ, IL-2, and GM-CSF, it is unlikely that this discrepancy accounted for the lack of correlation, as no correlation was observed for the individual cytokines. Indeed, TNF-α is reportedly more narrowly regulated by NFAT subtypes and thus might be a more potent driver of MRE. 30 Beyond static patient factors like genotype-determined tacrolimus sensitivity, a number of clinical factors, including age, medical comorbidities, acute and chronic infections, and tacrolimus pharmacokinetics, could contribute to the observed substantial variation in MRE between individuals.
In conclusion, these data demonstrate the potential clinical utility of MRE measurement in lung allograft recipients to identify subjects at increased risk for infection, as well as its limitations.
Interestingly, we found that this assay was dependent on prednisone dose, suggesting an interaction between the tacrolimus and prednisone signaling pathways in modulating NFAT-related gene expression. These studies highlight the inadequacies of current methods for lung transplant immunosuppression monitoring and suggest that strategies to characterize the degree of immunosuppression could be of value in lung transplant recipients. 
